How to Apply to UCB

14 min read Last updated April 20, 2026 257 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Apply once through careers.ucb.com — do not duplicate applications across affiliates.
  • Build real depth in either immunology (Bimzelx, Cimzia, dual IL-17A/F) or neurology (epilepsy portfolio, Vimpat post-LOE dynamics, Briviact, Neurona acquisition) before interviewing.
  • Front-load your CV with the diseases, mechanisms, and brands you have actually worked on.
  • Speak the Patient Value Strategy language with specifics, not platitudes — name patients, burdens, unmet needs.
  • Prepare a concrete answer for why UCB versus AbbVie, Lilly, J&J, Novartis, or Sanofi.
  • For US Atlanta roles, lead with launch and specialty access metrics; for Brussels and Slough, lead with collaboration, science, and global operating experience.
  • Mirror UCB's value language (Inspired by Patients and Driven by Science, Together is Better, Brave to Lead and Brave to Care) without mechanical recitation.
  • Be honest about French or Dutch fluency — useful but not required; misrepresentation surfaces fast.
  • Calibrate compensation expectations to the relevant labor market: Belgian framework in Brussels, US specialty-pharma benchmarks in Atlanta, UK in Slough — not a single global scale.

About UCB

UCB SA (Euronext Brussels: UCB) is a Belgian global biopharmaceutical company headquartered in Brussels, Belgium, founded in 1928 as Union Chimique Belge and reshaped over the last three decades into a focused specialty biopharma operating in immunology and neurology. The company employs roughly 9,000 people across major sites in Brussels (corporate and R&D headquarters), Atlanta, Georgia (Americas headquarters and Patient Value organization for North America), Slough in the United Kingdom (large R&D and manufacturing footprint inherited from the Celltech acquisition), Tokyo (Japan affiliate), and Shanghai (China affiliate), with additional commercial affiliates across Europe, Latin America, Asia-Pacific, and the Middle East. UCB has spent the last decade deliberately concentrating its portfolio around two therapeutic areas — severe immune disorders and severe diseases of the nervous system — and divesting peripheral assets to fund a generation of biologic launches. The flagship products that candidates need to understand cold are Cimzia (certolizumab pegol), the long-running PEGylated anti-TNF franchise indicated across rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, plaque psoriasis, and Crohn's disease, which has historically anchored UCB's immunology revenue; Bimzelx (bimekizumab), the dual IL-17A and IL-17F inhibitor first approved in Europe in 2021 and in the United States in October 2023 for plaque psoriasis, with successive label expansions through 2024 into psoriatic arthritis, axial spondyloarthritis, and most consequentially hidradenitis suppurativa (FDA approval November 2024); Vimpat (lacosamide), the anti-seizure medication that lost United States patent exclusivity in March 2022 and has been in steep generic erosion ever since; Briviact (brivaracetam), the more recent anti-seizure medication still under exclusivity; and the heritage Keppra (levetiracetam) franchise that established UCB's epilepsy credibility in the 2000s. The strategic story to underwrite is direct: Vimpat's US loss of exclusivity created a multi-year revenue gap that the Bimzelx franchise is now expected to fill and exceed, and the November 2024 hidradenitis suppurativa approval — the first dual IL-17A/F mechanism approved in HS, against an under-served patient population — is the single largest commercial bet on the company's near-term trajectory. Bimzelx revenue scaled from approximately 600 million euros in 2024 to roughly 2.2 billion euros in 2025, with United States net sales the dominant driver, and UCB has correspondingly expanded its dermatology and rheumatology field forces in the US and EU to support the launch. UCB also continues to invest in epilepsy through its November 2024 acquisition of Neurona Therapeutics' regenerative cell therapy program (NRTX-1001), in osteoporosis through Evenity (romosozumab, partnered with Amgen), and in a long-tail rare-disease pipeline including Rystiggo (rozanolixizumab) for myasthenia gravis. Jean-Christophe Tellier — a French rheumatologist by training — has served as Chief Executive Officer since January 2015 and was renewed by the Board for a further four-year term running through the 2030 Annual General Meeting; this matters to candidates because it signals continuity of strategy through the entire Bimzelx scale-up. The company competes directly with AbbVie (Humira / Skyrizi / Rinvoq), Johnson & Johnson (Tremfya / Stelara), Eli Lilly (Taltz), Novartis (Cosentyx), and Sanofi/Regeneron (Dupixent) in inflammation and immunology, and against UCB's own legacy generics-and-Keppra installed base plus newer entrants in neurology. UCB is, in honest framing, mid-cap by global pharma standards — large enough to run global launches and operate its own manufacturing and clinical infrastructure, small enough that individual contributors and managers can see their work move enterprise outcomes. Pay sits competitive with European specialty pharma peers (Novo Nordisk, Lundbeck, Almirall, Ipsen) and somewhat below US large-cap biotech in absolute base salary, with Belgian and US benefits stacks that close more of the gap than headline numbers suggest.

Application Process

  1. 1
    Search and apply on the official career site at careers

    Search and apply on the official career site at careers.ucb.com. UCB consolidated all global hiring through this single Phenom-powered career site, which fronts an SAP SuccessFactors backend. Applications submitted to country affiliates eventually flow through the same system, so apply once through careers.ucb.com rather than emailing local recruiters.

  2. 2
    Create a candidate profile and upload a single up-to-date PDF resume

    Create a candidate profile and upload a single up-to-date PDF resume. The Phenom apply flow is intentionally short — UCB publicly cut its time-to-apply from roughly 20 minutes to under 5 minutes by reducing form fields. Do not upload multiple versions of your resume across multiple applications; the recruiter sees your full application history under a single profile.

  3. 3
    Recruiter screen by phone or video, typically 30 minutes

    Recruiter screen by phone or video, typically 30 minutes. Conducted by the Talent Acquisition partner aligned to the function and region. Expect motivation, geographic flexibility, work authorization, salary expectations, and a high-level walk through your most recent two to three roles.

  4. 4
    Hiring manager interview, usually 45 to 60 minutes by video

    Hiring manager interview, usually 45 to 60 minutes by video. The hiring manager probes therapeutic-area fit, technical depth, and how your specific experience maps to the open requisition. For commercial and medical affairs roles in immunology, expect to discuss the dual IL-17A/F mechanism, the Bimzelx label expansions, and how you have handled launch dynamics or post-launch optimization.

  5. 5
    Panel or loop interviews with cross-functional stakeholders

    Panel or loop interviews with cross-functional stakeholders. Three to five additional interviews across peers, downstream and upstream functions, and a senior leader. UCB explicitly screens for collaboration across R&D, medical, commercial, market access, and patient advocacy — siloed answers are scored down. Behavioral questions are organized around UCB's stated values: Patient Value, Inspired by Patients and Driven by Science, Together is Better, Brave to Lead and Brave to Care.

  6. 6
    Assessment exercise where relevant

    Assessment exercise where relevant. Commercial roles may be asked to deliver a brand or launch case, medical affairs candidates may be asked to present on a clinical paper or therapeutic-area landscape, R&D candidates may be asked to deliver a chalk talk on their published or unpublished work. Bring a printed or shareable backup; technology failures during virtual presentations are common and recoverable.

  7. 7
    Final values and culture conversation, often with a senior site or function lead

    Final values and culture conversation, often with a senior site or function leader, sometimes including a People Solutions (HR) business partner. Expect explicit conversation about UCB's Patient Value Strategy and how you would operationalize it inside the role.

  8. 8
    Offer, background verification, and onboarding

    Offer, background verification, and onboarding. Belgian offers move through the country labor framework (typically a CDI / open-ended contract with 13th month, meal vouchers, hospitalization insurance, group pension, and statutory paid leave). US offers move through the standard Atlanta-based People Solutions team with offer letter, background and education verification, drug screen where role-required, and I-9. UK offers through Slough use UK statutory frameworks with private medical, pension, and life assurance. Onboarding includes a Patient Value induction that all new hires across geographies complete in the first 90 days.

Resume Tips for UCB

recommended

Lead with therapeutic area, not function

Lead with therapeutic area, not function. UCB hires deeply into immunology (psoriasis, psoriatic arthritis, axial spondyloarthritis, rheumatoid arthritis, hidradenitis suppurativa, Crohn's disease, myasthenia gravis) and neurology (epilepsy across focal and generalized seizures, Parkinson's adjacencies). Front-load your CV with the diseases and mechanisms you have actually worked on rather than burying them under generic role titles.

recommended

For commercial, marketing, and sales roles foreground biologic launch experience

For commercial, marketing, and sales roles foreground biologic launch experience. Quantify share gain, formulary wins, payer access metrics, sales rep productivity, KOL engagement counts, and digital channel adoption. UCB has publicly stated that digital tools accounted for over 45 percent of its HCP interactions in 2024, so demonstrated comfort with omnichannel execution is genuinely differentiating.

recommended

For medical affairs and field medical roles, name the specific therapeutic-area

For medical affairs and field medical roles, name the specific therapeutic-area societies you engage (AAD, EADV, ACR, EULAR, AAN, ILAE, AAO-HNS for HS), the advisory boards you have moderated, the publications you have authored or supported, and the medical strategy frameworks you have run (medical plan, evidence generation plan, scientific platform).

recommended

For clinical development, regulatory affairs, and pharmacovigilance, list the IN

For clinical development, regulatory affairs, and pharmacovigilance, list the IND, NDA, BLA, MAA, sBLA, and JPDA submissions you have contributed to and the specific modules or sections you owned. UCB runs global filings — FDA, EMA, MHRA, PMDA, NMPA — so multi-jurisdictional experience is a differentiator.

recommended

For research, discovery, translational sciences, and CMC roles, list dissertatio

For research, discovery, translational sciences, and CMC roles, list dissertation work, advisor, and three highest-impact publications with citation counts. UCB's biologics platform is large enough to value protein engineering, antibody discovery, biophysics, and cell therapy depth — name the modalities you have hands-on with.

recommended

For Slough-based UK roles, signal hands-on biologics manufacturing, fill-finish,

For Slough-based UK roles, signal hands-on biologics manufacturing, fill-finish, or commercial-scale process science experience where relevant. The Slough site carries the Celltech inheritance and remains a central biologics R&D and manufacturing hub.

recommended

For Brussels HQ and Belgian field roles, English is the working corporate langua

For Brussels HQ and Belgian field roles, English is the working corporate language and is sufficient for almost all roles, but functional French or Dutch is genuinely useful and worth listing honestly if you have it. Do not overstate; misrepresentation surfaces in early small-talk with Belgian colleagues.

recommended

For Atlanta-based US roles, US specialty pharma launch and access experience is

For Atlanta-based US roles, US specialty pharma launch and access experience is the dominant resume signal — name the manufacturers you have worked at, the brands, the indications, and the specific specialty pharmacy and hub services partners you have managed (CVS Specialty, Accredo, Walgreens AllianceRx, AssistRx, CareMetx).

recommended

Use UCB's actual language

Use UCB's actual language. The corporate vocabulary — Patient Value Strategy, Inspired by Patients and Driven by Science, Brave to Lead and Brave to Care, Together is Better — is not decoration; it is the operating language used in interviews, performance reviews, and internal town halls. Mirror it intentionally without sounding mechanical.

ATS System: Phenom (career site experience) on SAP SuccessFactors (ATS backbone)

UCB consolidated all global external hiring through a single Phenom-powered career site at careers.ucb.com, with SAP SuccessFactors as the underlying applicant tracking system that holds requisitions, candidate records, and recruiter workflow. UCB publicly cut its candidate time-to-apply from roughly 20 minutes to under 5 minutes by redesigning the apply flow on Phenom and removing form-field friction. The Phenom front-end also powers job recommendations, candidate profile management, talent communities, and the career site search experience. All country affiliates — Brussels HQ, Atlanta Americas HQ, Slough UK, Tokyo, Shanghai, and the broader European, LATAM, and APAC commercial affiliates — route through the same global system, so candidates should apply once through careers.ucb.com rather than emailing local recruiters or applying through country-specific subsidiary pages.

  • Apply through careers.ucb.com — the single global portal — not through country-affiliate websites or third-party aggregators that may lag the canonical posting.
  • Create one candidate profile under one email address; multiple fragmented profiles read as disorganized to recruiters and obscure your full application history.
  • Upload a single clean PDF resume under 2 MB with the file naming pattern FirstName-LastName-Resume.pdf — Phenom and SuccessFactors both parse PDF reliably; avoid Word documents and image-based scans.
  • Use the Phenom job alerts feature aggressively for therapeutic-area or function-specific saved searches — UCB posts requisitions in waves tied to launch milestones and pipeline progression, so timely notification matters.
  • On the apply form, complete the optional fields (LinkedIn URL, professional summary, willingness to relocate) — they are scored by the recruiter's downstream workflow even though they are optional at submission.
  • Reference an internal contact in the application form if you have one; UCB runs a structured employee referral program through SuccessFactors and referrals are surfaced in the recruiter view.

Complete Phenom (career site experience) on SAP SuccessFactors (ATS backbone) Resume Guide →

Interview Culture

UCB interviews carry a recognizable European specialty-pharma cadence — measured, evidence-driven, collaborative, with explicit time given to values fit — overlaid with a US-style commercial intensity in the Atlanta-based Patient Value organization that runs the Bimzelx US launch. The dominant cultural framework you will hear referenced repeatedly is the Patient Value Strategy: UCB orients its product portfolio, its R&D bets, its commercial decisions, and its individual performance objectives around delivering measurable value to patients living with severe diseases, and interviewers will explicitly probe whether candidates can articulate their role through that lens. Generic answers about helping people are scored down; specific answers — naming a patient population, a disease burden statistic, an unmet need, a quality-of-life endpoint, an access barrier — are scored up. Behavioral questioning follows the values framework directly: Inspired by Patients and Driven by Science (probing scientific rigor and patient orientation simultaneously), Together is Better (probing genuine cross-functional collaboration, not lip service), Brave to Lead and Brave to Care (probing willingness to make hard calls and willingness to absorb the human cost of those calls). Expect at least one question per value, framed as an experience-based STAR-format prompt. Therapeutic-area depth matters more at UCB than at a generalist big pharma because the portfolio is concentrated. For immunology candidates this means real fluency in the IL-17A/F dual-inhibition rationale and how Bimzelx differentiates against IL-17A-only inhibition (Cosentyx, Taltz), IL-23 inhibition (Skyrizi, Tremfya, Stelara), TNF inhibition (Humira, Cimzia), and JAK inhibition (Rinvoq, Olumiant); the hidradenitis suppurativa unmet need and the patient journey through dermatology referral patterns; and the European versus US payer landscape for biologics. For neurology candidates this means epilepsy depth — focal versus generalized seizures, refractory patient flow, the historical anti-seizure medication generations, the Vimpat loss-of-exclusivity dynamic, and where Briviact and the legacy Keppra franchise sit competitively against UCB's own assets and against newer entrants. The acquisition of Neurona Therapeutics in November 2024 has also raised the salience of cell-therapy literacy for senior R&D and clinical candidates. Cross-functional collaboration is tested directly. UCB explicitly operates through joint Patient Value Units that span R&D, medical, commercial, access, and patient advocacy; candidates who describe past success exclusively through the lens of their own function — without naming partner functions, joint deliverables, and how they navigated disagreement — are read as risk. Brussels and Slough interviews lean slightly more consensus-oriented, with more time given to how you reach decisions and bring stakeholders along. Atlanta and US field interviews lean slightly more results-oriented and pace-sensitive, with more time given to what you delivered and how fast. Both styles converge on the same standard: clear evidence, intellectual honesty, and authentic patient orientation. Expect to be asked, in some form, why UCB rather than AbbVie, Lilly, J&J, Novartis, or Sanofi — having a real, specific, non-generic answer (the dual IL-17A/F differentiation, the focused portfolio, the patient-organization relationships, the Belgian heritage with global ambition) is read as preparation; not having one is read as casual interest. Interviewers also pay attention to how you handle ambiguity in pipeline questions you cannot fully answer — saying you do not know and explaining how you would find out is scored higher than confident speculation.

What UCB Looks For

  • Genuine, specific patient orientation — the ability to ground your motivation and your work in named patient populations, disease burden, and unmet need rather than generic helping language.
  • Therapeutic-area depth in immunology, neurology, or both — UCB hires for portfolio fit, not transferable skill alone.
  • Cross-functional collaboration evidence — concrete examples of working with R&D, medical, commercial, access, and patient advocacy partners on joint deliverables.
  • Scientific rigor at global biopharma standard — for R&D and medical roles, peer-reviewed publication record and the ability to defend experimental design and data interpretation.
  • Launch and post-launch commercial DNA — for commercial and access roles, demonstrated experience in biologic launches with quantified outcomes.
  • Multi-jurisdictional regulatory and clinical operations literacy — FDA, EMA, MHRA, PMDA, NMPA experience as relevant to the role.
  • Comfort with European corporate culture and English as the working language — most roles do not require French or Dutch, but cultural adaptability across Brussels, Slough, Atlanta, Tokyo, and Shanghai matters.
  • Authentic alignment with the Patient Value vocabulary — not mechanical recitation of the values, but evidence you have already operated this way.
  • Intellectual honesty about what you know and do not know — confident bluffing on pipeline or science questions is a negative signal.

Frequently Asked Questions

What ATS does UCB use and how does the Phenom apply flow actually work?
UCB's external careers experience at careers.ucb.com is powered by Phenom's Intelligent Talent Experience platform, sitting on top of SAP SuccessFactors as the underlying applicant tracking system. The Phenom front-end handles search, recommendations, candidate profile, and the apply flow itself, while SuccessFactors holds the requisition, candidate record, and downstream workflow used by recruiters and hiring managers. UCB publicly stated that the Phenom redesign cut time-to-apply from roughly 20 minutes to under 5 minutes by removing friction and form fields. Practically, this means: create a single profile under one email address, upload one clean PDF resume, and apply directly to specific requisitions. Avoid creating multiple profiles; the recruiter sees your full application history under one profile and a fragmented record reads as disorganized.
Is UCB still a Belgian company in any meaningful sense, or is it really run from the United States now?
UCB remains genuinely headquartered in Brussels, listed on Euronext Brussels as UCB, governed by Belgian corporate law, and led by a French CEO based in Brussels. The Brussels site holds corporate functions, a large R&D footprint, and the global executive team. That said, the United States is the largest single revenue market and houses the Patient Value organization for North America in Atlanta, Georgia, where Bimzelx commercial leadership, US medical affairs, US market access, and a substantial portion of the field force are based. The honest framing is that UCB is a Belgian company with a US commercial center of gravity for its largest growth product. Strategy is set in Brussels; US execution is run from Atlanta. Slough in the UK carries the Celltech-inherited biologics R&D and manufacturing weight. Tokyo and Shanghai run the Asian commercial affiliates. Candidates picking a location should pick by the function and the product they want to work on, not by the assumption that one site is the real one.
What does compensation look like across UCB's main sites?
Compensation varies meaningfully by labor market and is benchmarked locally rather than globally. In Brussels and Belgium broadly, salaries follow Belgian biopharma norms and are paid as gross annual salary with a 13th month, meal vouchers, eco vouchers, hospitalization insurance, supplementary pension, statutory holiday and vacation pay; total cash comp for senior individual contributor scientists and managers commonly lands in the 80,000 to 140,000 euro range, with senior directors and global heads materially above. In Atlanta and US-based commercial roles, compensation benchmarks against US specialty pharma peers (AbbVie, Lilly, J&J, Novartis US, Sanofi US): base salaries roughly 130,000 to 220,000 USD for senior managers and directors in commercial, medical affairs, and access; sales representatives carry the standard specialty-pharma base plus variable commission structure; long-term incentive in restricted stock units. In Slough UK, salaries follow UK pharma scale with private medical, pension, life assurance, and 25 to 30 days statutory holiday. Asia-Pacific affiliates pay to local market. The cross-site gap is real and well-known internally; do not expect a Brussels offer to match an Atlanta offer for the same nominal title.
How important is the Bimzelx hidradenitis suppurativa launch for candidates joining now?
It is the single most consequential commercial bet on the company's near-term trajectory and shapes hiring across multiple functions. The FDA approved Bimzelx for moderate-to-severe hidradenitis suppurativa in November 2024, making it the first dual IL-17A and IL-17F inhibitor approved in the indication and addressing a meaningfully under-served patient population that has historically had only TNF inhibition (Humira) and one IL-17A inhibitor (Cosentyx, approved later) as biologic options. UCB has expanded its US dermatology field force to support the launch and has invested heavily in HS-specific medical affairs, patient advocacy partnerships (HS Foundation, Hope for HS), specialty access infrastructure, and KOL development. For commercial, medical, and access candidates this means HS-specific roles are actively being filled and HS therapeutic-area literacy is a strong differentiator. For R&D and regulatory candidates the HS approval signals continued investment in the dual-mechanism franchise across additional indications. Bimzelx revenue scaled from approximately 600 million euros in 2024 to roughly 2.2 billion euros in 2025, with US net sales the dominant driver, validating the launch thesis.
How worried should candidates be about the Vimpat loss-of-exclusivity?
Vimpat lost United States patent exclusivity in March 2022 and has been in steep generic erosion ever since, creating a multi-year revenue gap that UCB has been transparent about with investors. The strategic answer is that the Bimzelx franchise — with successive label expansions through 2024 culminating in the November 2024 hidradenitis suppurativa approval — is now expected to fill and exceed that gap, and 2025 financial results have validated that thesis. From a candidate perspective, the practical implication is that neurology hiring continues but is more focused on Briviact, on the Neurona Therapeutics cell-therapy program acquired in November 2024, and on long-horizon pipeline assets, rather than on Vimpat lifecycle management. Roles tied directly to Vimpat US lifecycle work are limited. Candidates choosing between immunology and neurology tracks at UCB should be honest with themselves about which side of the portfolio is hiring and growing fastest.
Does UCB hire foreign nationals into Brussels and how does Belgian work authorization actually work?
Yes. UCB hires meaningful numbers of foreign nationals into Brussels HQ for global functions, R&D, and corporate roles. Within the European Union and EEA, freedom of movement applies and no separate work permit is required. For non-EU nationals UCB sponsors Belgian work authorization, typically through the Single Permit (Combined Permit for Work and Residence) route administered at the regional level (Brussels-Capital Region for Brussels-based roles), which combines work authorization and residence permit into a single application. For highly qualified roles UCB also uses the EU Blue Card pathway. Sponsorship is offered case-by-case, almost always for roles where the global talent pool — not the Belgian or EU pool — is the relevant supply. English is the working corporate language at Brussels HQ; functional French or Dutch is useful for daily life and client-facing internal interactions but is not required for most global roles. Onboarding includes practical Belgian relocation support (housing search assistance, school recommendations, banking and tax setup).
How is the recent leadership rotation likely to affect interviews and hiring?
On 6 November 2025 UCB announced an executive team rotation effective 1 January 2026: Fiona du Monceau moved into the Executive Vice President and Chief Commercial Officer role, and Emmanuel Caeymaex moved from Chief Commercial Officer into Executive Vice President, Head of Patient Evidence. CEO Jean-Christophe Tellier was renewed by the Board for a further four-year term running through the 2030 Annual General Meeting, which signals continuity of strategy through the entire Bimzelx scale-up rather than a leadership transition. For candidates the practical implications are: commercial organization design and metrics under Fiona du Monceau may evolve through 2026, so commercial interviewees should expect questions about how they would partner with a new commercial leadership posture; Patient Evidence (real-world evidence, health economics, outcomes research, registries) is now elevated as an executive function under Emmanuel Caeymaex, which raises the strategic salience of evidence-generation roles. CEO continuity through 2030 is a stable base for everyone else.
How competitive is the talent landscape for Bimzelx commercial and medical hires versus Humira biosimilars and IL-17/IL-23 competitors?
Highly competitive in the United States and Europe, particularly in dermatology, rheumatology, and gastroenterology field roles. UCB is hiring against AbbVie's Skyrizi and Rinvoq franchise machines, Eli Lilly's Taltz organization, Novartis's Cosentyx team, Johnson and Johnson's Tremfya and Stelara organizations, and Sanofi/Regeneron's Dupixent organization in adjacent indications. Recruiters routinely engage candidates currently working on these competing biologics. UCB's differentiation pitch to candidates centers on the focused portfolio (less internal competition for prioritization than at a 30-asset Big Pharma), the dual IL-17A/F mechanism story, the under-served HS patient population, and the genuine patient-value culture that the company has invested in for over a decade. Pay is competitive with peers but rarely the highest in any given offer round; the case for joining is portfolio fit and culture, not headline number. Candidates negotiating offers should benchmark across multiple peers and be honest about what they value.
What does the Atlanta site actually do, and is it different from Brussels in interview style?
Atlanta is the headquarters of UCB's Patient Value organization for North America and houses US commercial leadership, US medical affairs, US market access, US patient services, US regulatory liaison, and a substantial portion of the field-aligned home office. It also houses the Bimzelx US launch operations and the largest US-based concentration of UCB employees. Interview style in Atlanta leans more US-pharma in pace and tone — faster turnaround between rounds, more emphasis on quantified launch metrics and territory-level outcomes, more direct conversation about variable compensation and career trajectory, more time on specialty pharmacy and payer access mechanics. Brussels by contrast leans more consensus-oriented and evidence-driven, with more time given to how you build cross-functional buy-in and how you reason through ambiguity. Both styles converge on the same Patient Value standard. Candidates with US commercial backgrounds typically find Atlanta more familiar; candidates with European corporate or global R&D backgrounds typically find Brussels more familiar. Pick the site where the role you actually want sits, not where the cultural fit feels most comfortable on paper.

Open Positions

UCB currently has 257 open positions.

Check Your Resume Before Applying → View 257 open positions at UCB

Related Resources

Similar Companies

Sources

  1. —
  2. —
  3. —
  4. —
  5. —
  6. —
  7. —
  8. —
  9. —